This article is made available for a limited time sponsored by ACS under the ACS Free to Read License, which permits copying and redistribution of the article for non-commercial scholarly purposes.
Editorial pubs.acs.org/ptsci
Cite This: ACS Pharmacol. Transl. Sci. 2019, 2, 1−1
ACS Pharmacology & Translational Science in 2019
Downloaded via 109.94.174.87 on February 13, 2019 at 08:34:12 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles.
A
dyskinesias linked to dopamine system dysregulation. In the work of Dal Maso and colleagues (Dal Maso et al., 2019),4 quantitative analytical pharmacology was used in combination with receptor mutagenesis and improved resolution of the cryo-EM structure of the calcitonin receptor to understand the dynamics of receptor activation by different ligands, highlighting complexities in structure-based drug design for this, and related, peptide receptors. The work of Ruan and colleagues (Ruan et al., 2019),5 combined molecular studies with preclinical animal models to illustrate how polypharmacology was required for anticancer efficacy of kidney-type transglutaminase inhibitors, providing a potential path to new therapies.
s we move into 2019 we are excited to announce a number of initiatives within ACS Pharmacology & Translational Science including two special issues that will be published later in 2019. The first of these will be on “Recent Advances in Cardiovascular Biology” and will be Guest Edited by our Associate Editor Kathleen Caron from the University of North Carolina. We are seeking manuscripts within the broad discipline of cardiovascular biology, with the goal of highlighting several of the most recent technological and conceptual breakthroughs that elucidate mechanistic pathways of pathophysiology. Areas of particular interest include single cell analysis of cardiovascular organs in health and disease, endothelial cell heterogeneity in specialized vascular beds, regenerative potential and pathways, the regulation and consequences of sex differences, rare diseases of cardiovascular dysfunction, and metabolism. Studies that focus on therapeutic targets are of particular interest, though manuscripts that describe foundational discoveries will also be considered. The second will be in the general area of “Protein Phosphorylation”, with manuscripts exploring the complex role that dynamic changes in protein phosphorylation have in controlling cellular function. This special issue will be Guest Edited by Andrew Tobin and Sophie Bradley from the University of Glasgow. We will also be publishing a virtual issue on G proteincoupled receptors in December of 2019, collating the important papers published in this research domain during 2019. Excitingly, the virtual issue will become live from April, providing an easy link for readers to find these papers. Finally, we will be commencing a series on “Drug Discovery Stories” for which key researchers involved in the discovery and development of new medicines will be invited to describe the key events that allowed these discoveries to become medicines. We look forward to submissions and ideas for these new initiatives. Of course, as always, we welcome all quality, innovative research across the basic and preclinical sciences in which the translational importance of the research is articulated. We welcome presubmission enquiries if you are not sure whether your research is within the journal scope.
■
Patrick M. Sexton, Editor-in-Chief AUTHOR INFORMATION
Notes
Views expressed in this editorial are those of the author and not necessarily the views of the ACS.
■
REFERENCES
(1) Russo, A. F. (2019) CGRP-Based Migraine Therapeutics: How Might They Work, Why So Safe, and What Next? ACS Pharmacol. Transl. Sci., DOI: 10.1021/acsptsci.8b00036. (2) Kenakin, T. (2019) Analytical Pharmacology: How Numbers Can Guide Drug Discovery. ACS Pharmacol. Transl. Sci., DOI: 10.1021/acsptsci.8b00057. (3) Bonifazi, A. (2019) Novel and Potent D2 receptor (D2R) Goprotein biased agonists. ACS Pharmacol. Transl. Sci., DOI: 10.1021/ acsptsci.8b00060. (4) Dal Maso, E. (2019) The Molecular Control of Calcitonin Receptor Signaling. ACS Pharmacol. Transl. Sci., DOI: 10.1021/ acsptsci.8b00056. (5) Ruan, J. J. (2019) Kidney Type Glutaminase Inhibitor Hexylselen Selectively Kills Cancer Cells via a Three-Pronged Mechanism. ACS Pharmacol. Transl. Sci., DOI: 10.1021/acsptsci.8b00047.
■
HIGHLIGHTS OF THE 2019 FIRST ISSUE In the first issue for 2019 Andrew Russo provides a timely perspective on migraine therapeutics, focusing on the new class of CGRP-targeted therapies that represent a major breakthrough for this debilitating disease (Russo, A., 2019),1 and renowned analytical pharmacologist, Terry Kenakin, explains the importance of quantitative analyses in understanding drug behavior and the drug discovery process (Kenakin T., 2019).2 The importance of such quantitative approaches was illustrated in the work of Bonifazi and colleagues (Bonifazi et al., 2019),3 who combined medicinal chemistry with multipathway analyses to identify novel G protein biased dopamine D2 receptor agonists that have potential utility in treatment of © 2019 American Chemical Society
Received: January 19, 2019 Published: February 8, 2019 1
DOI: 10.1021/acsptsci.9b00005 ACS Pharmacol. Transl. Sci. 2019, 2, 1−1
